Skip to Main Content

CytoDyn CEO Nader Pourhassan used a conference call on Thursday evening to claim success with the company’s experimental Covid-19 drug — but his description of the clinical data, if true, suggests the drug didn’t meet the study’s primary goal.

In disjointed comments to investors, Pourhassan insisted that leronlimab delivered “positive efficacy results” in the Covid-19 study. CytoDyn intended to quickly submit the “strong results” to the Food and Drug Administration and expected to win approval for leronlimab as a new treatment for Covid-19, he added.


But in describing the leronlimab data, Pourhassan only said the drug improved symptoms after three days, not the 14 days set as the study’s endpoint. If that’s the case, it would suggest the 75-person trial failed to achieve its primary goal. Generally, the FDA does not approve drugs which cannot prove a benefit for patients, even those with Covid-19.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.